Updated time: 2024-11-15 11:32:05
28A-1060710
TW I696634、US 12,103,969 B2
Hepatitis B virus (HBV) infection is a global health problem which causes liver diseases including acute or chronic HBV infection, liver cirrhosis and/or hepatocellular carcinoma (HCC). During HBV infection, large amount of viral proteins, including surface antigen (HBsAg), are produced and demonstrated to have immunosuppressive functions in innate immune cells. Several studies have shown that HBV may inhibit TLR-mediated downstream pathways via its viral proteins. Sialic acid-binding Immunoglobulin-like lectins (SIGLEC) are transmembrane receptors expressed on several types of cells, including immune cells, which signal negatively through their Immunoreceptor tyrosine-based inhibitory motif (ITIM) and result in attenuation of the signal transduction from pathways such as TLR-mediated one). Our study revealed that the sialic structures on HBsAg are similar to those of SIGLEC ligands. We showed that HBV binds to SIGLEC3 receptor. We had made anti-SIGLEC3 and identified the clone into agonist and blocking antibody. We demonstrated that anti-SIGLEC3 mAb (clone_10C8_) can block SIGLEC receptors and reverse the suppression of TNF-alpha in dendritic cells by HBV,
We prospect that these antibodies have the potential to treat HBV infected diseases. Besides the anti-SIGLEC3, agonist mAb can inhibit TLR2 ligand induced TNF-alpha secretion, which can suppress innate immune function and have the potential to treat autoimmune diseases
- Anti-SIGLEC3 mAb (clone: 10C8) can reverse the suppression of host immune function by HBV and treat HBV related hepatitis.
- Anti-SIGLEC3 mAb (clone: 2B9, 3B8, 4D2) can suppress host immune function, be a immunosuppressant drug and treat autoimmune diseases.
Shie-Liang Hsieh, Tsung-Yu Tsai, An-Suei, Yang, Chung-Ming Yu, Cheng-Yuan Peng
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

1.Human Anti-SIGLEC3 (Clone_10C8) can be used as a blocking antibody to treat HBV-related hepatitis disease. 2.Human anti-SIGLEC3 (Clone _2B9, 3B8, 4D2) can be used as an agonist antibody to treat autoimmune disease or as an immunosuppressant drug